Article metrics

Download PDFPDF

Original research
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

 

Online download statistics by month:

Online download statistics by month: April 2022 to March 2024

AbstractFullPdf
Apr 2022476477196
May 2022334336134
Jun 202219518274
Jul 202215015051
Aug 202211110734
Sep 202220519771
Oct 202216116260
Nov 20229910048
Dec 202210710237
Jan 202313412954
Feb 202313513586
Mar 202314914479
Apr 2023939143
May 2023949145
Jun 2023919034
Jul 2023666246
Aug 2023646236
Sep 2023555247
Oct 2023505047
Nov 2023585624
Dec 2023615644
Jan 2024504936
Feb 2024604940
Mar 2024746986
Total307229981452